Pharmacological clearance of senescent cells reduces inflammation, endothelial damage and cardiac fibrosis in HFpEF.

Elsa D Silva, Inês Tomé, Francisco Vasques-Nóvoa, Glória Conceição, Andreia Silva, António S Barros, Pedro Mendes-Ferreira, Diana Santos-Ribeiro, Alexandre Gonçalves, António Angélico-Gonçalves, Rui Adão, Carolina Caetano, Daniel Sousa, Daniela Miranda-Silva, Rio P Juni, Tamara Tchkonia, James L Kirkland, Francisco Caramelo, Nádia Gonçalves, Vasco Sampaio-Pinto, João S Ribeiro, Reinier A Boon, Adelino Leite-Moreira, Patrícia Pitrez, Perpétua Pinto-do-Ó, Susana G Santos, Inês Falcão-Pires, Lino Ferreira, Diana S Nascimento

i3S - Institute for Research and Innovation in Health, University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal.i3S - Institute for Research and Innovation in Health, University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal. · pubmed

Paper

Abstract

Heart failure with preserved ejection fraction (HFpEF) is one of the most common forms of heart failure with no effective treatment. While chronic systemic inflammation, triggered by comorbidities, is a critical factor of HFpEF pathophysiology and a relevant target for therapy, mechanisms underlying inflammation remain poorly understood. Here, we aim to understand the upstream mechanisms driving inflammation, including immune dysregulation and cellular senescence.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Pharmacological clearance of senescent cells can reduce inflammation and cardiac fibrosis in HFpEF. This research addresses cellular senescence, a key mechanism associated with aging and age-related diseases, making it relevant to longevity research.

Author of this paper? Send a correction.